We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Illumina Commences Shipment of the Human1M BeadChip

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Illumina, Inc. announced that it began shipment of the Human1M DNA analysis beadchip last week, a solution that contains more than one million single-nucleotide polymorphisms (SNPs) on a single chip.

In addition to targeting a catalog of known copy number variation (CNV) sites, the Human1M BeadChip contains CNV content, developed in collaboration with deCODE genetics and not currently available through any other array or public database.

The content of the Human1M BeadChip offers genomic coverage, power, and value per sample. Powered by the Infinium® assay, which has demonstrated superior performance and delivered robust data to customers, researchers are able to obtain and publish results in record-setting time.

"By taking a combined tagSNP, gene-centric, and evenly spaced approach, this BeadChip provides remarkable genomic-coverage, which is critical to uncovering the genetic basis of multiple human disorders," said David Duggan, Ph.D., Director of the Advanced Genomics Technology Center at the Translational Genomics Research Institute.

"For multiple studies, we have planned or are already underway, I am confident that the Human1M BeadChip will provide the statistical power to make breakthrough discoveries," said Duggan.

The Human1M BeadChip is a comprehensive genotyping research tool available for genome-wide association studies. When used with Illumina's integrated data analysis software tool, BeadStudio, CNVs and SNPs can be analyzed simultaneously for a view of DNA variation across the genome.

"Our products help researchers do breakthrough science. Illumina's Infinium products have been used to study genetic variants linked to Type-2 diabetes, breast and prostate cancer, inflammatory bowel disease, Crohn's disease, and other complex conditions," said Jay Flatley, President and Chief Executive Officer of Illumina.

"Results from these studies have been published in more than 20 peer-reviewed studies; this is the true barometer of the quality and power that Illumina's products have to offer. With the Human1M BeadChip, we believe we have delivered to the community the most powerful DNA Analysis tool to address any complex disease study with unmatched performance and total experiment cost," Mr. Flatley continued.